- Home
- HBT vs VOR Comparison
HBT vs VOR Comparison
Compare HBT & VOR Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | HBT | VOR |
|---|---|---|
| Founded | 1920 | 2015 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.2B | 1.3B |
| IPO Year | 2019 | 2021 |
Fundamental Metrics
Financial Performance| Metric | HBT | VOR |
|---|---|---|
| Price | $37.16 | $23.05 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 5 | 10 |
| Target Price | $30.75 | ★ $45.33 |
| AVG Volume (30 Days) | 131.4K | ★ 820.5K |
| Earning Date | 04-27-2026 | 05-11-2026 |
| Dividend Yield | ★ 3.29% | N/A |
| EPS Growth | ★ 7.96 | N/A |
| EPS | ★ 1.12 | N/A |
| Revenue | N/A | N/A |
| Revenue This Year | $35.73 | N/A |
| Revenue Next Year | $7.01 | N/A |
| P/E Ratio | $33.23 | ★ N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $22.36 | $1.90 |
| 52 Week High | $37.38 | $49.95 |
Technical Indicators
Market Signals| Indicator | HBT | VOR |
|---|---|---|
| Relative Strength Index (RSI) | 73.36 | 62.61 |
| Support Level | $31.43 | $11.62 |
| Resistance Level | N/A | $24.34 |
| Average True Range (ATR) | 0.82 | 1.43 |
| MACD | 0.01 | 0.03 |
| Stochastic Oscillator | 86.35 | 76.60 |
Price Performance
Historical ComparisonAbout HBT HBT Financial Inc.
HBT Financial Inc provides a comprehensive suite of business, commercial, wealth management, and retail banking products and services to individuals, businesses, and municipal entities throughout Central and Northeastern Illinois and Eastern Iowa. It operates through one reportable segment: community banking. It generates revenue from Card income, Wealth management fees, and Service charges on deposit accounts.
About VOR Vor Biopharma Inc.
Vor Biopharma Inc is a clinical-stage biopharmaceutical company focused on developing novel therapies for the treatment of autoimmune diseases. Its program, telitacicept, is a potential first- and best-in-class dual BAFF/APRIL inhibitor designed to suppress the signaling pathways that drive the maturation, proliferation, and survival of harmful B cells, including self-reactive B cells, thereby reducing autoantibody production and preventing downstream tissue damage.